Version 1
: Received: 23 April 2022 / Approved: 26 April 2022 / Online: 26 April 2022 (04:07:48 CEST)
How to cite:
Bai, Y.; Zhang, X.; Yang, M.; Zhang, L.; Jia, X. Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19. Preprints2022, 2022040225. https://doi.org/10.20944/preprints202204.0225.v1
Bai, Y.; Zhang, X.; Yang, M.; Zhang, L.; Jia, X. Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19. Preprints 2022, 2022040225. https://doi.org/10.20944/preprints202204.0225.v1
Bai, Y.; Zhang, X.; Yang, M.; Zhang, L.; Jia, X. Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19. Preprints2022, 2022040225. https://doi.org/10.20944/preprints202204.0225.v1
APA Style
Bai, Y., Zhang, X., Yang, M., Zhang, L., & Jia, X. (2022). Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19. Preprints. https://doi.org/10.20944/preprints202204.0225.v1
Chicago/Turabian Style
Bai, Y., Lin Zhang and Xu Jia. 2022 "Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19" Preprints. https://doi.org/10.20944/preprints202204.0225.v1
Abstract
Background The spread of COVID-19 continues, the mutation of SARS-COV-2 is still difficult to control, and the need for antiviral drugs to treat COVID-19 remains urgent. The use of arbidol in the treatment of COVID-19 is limited and controversial. Methods To clarify the efficacy of arbidol on COVID-19, we collected 25 cases and 178 related studies. We analyzed the treatment information of arbidol based on the obtained cases, expanded the scope of the study, and collected current studies on the treatment of COVID-19 in various databases for in-depth analysis. Results History analysis showed that arbidol was effective (76% cure rate) compared with other drugs. However, compared with other antiviral drugs or standard therapy, the arbidol group had no significant advantage in reducing the time to negative virus transformation, length of hospital stays, or improvement in CT (MD=0.22, 95%CI -0.29-0.73; MD = 0.61, 95% CI 1.46 to 2.67; RR=1.15, 95%CI 0.88-1.50); Analysis of adverse events showed no significant difference between the arbidol group and the other groups (RR=0.82, 95%CI 0.25-2.71). Conclusion Our study showed that arbidol had no significant effect on COVID-19, but showed a slight advantage in CT improvement and adverse events. Our study objectively evaluated the efficacy of arbidol in the treatment of COVID-19 and provided some guidance for arbidol in the treatment of COVID-19.
Keywords
COVID-19; SARS-Cov-2; arbidol; treatment
Subject
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
